-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse Börse FrankfurtEURISIN JP3160400002-
Eisai Co., Ltd.Börse Japan Exchange Group TokioJPYISIN JP3160400002
-
EisaiBörse Börse FrankfurtISIN JP3160400002 WKN: 855526EURSymbol EII
-
EISAI CO LTDBörse Börse DüsseldorfEURSymbol EII
-
EISAI CO LTDBörse Börse BerlinEURSymbol EII
-
EISAI CO LTDBörse Börse MünchenEURSymbol EII
-
EISAI CO LTDBörse Börse StuttgartEURSymbol EII
-
EISAI CO LTDBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol EII
-
EISAI CO LTDBörse Gettex System der Börse MünchenEURSymbol EII
-
Eisai Co., Ltd.Börse Amerikanscher Freiverkehr OTC oder "Pink Sheets"USDISIN JP3160400002
-
USDEisai Co., Ltd.Börse Amerikanscher Freiverkehr OTC oder "Pink Sheets"
-
Eisai Co., Ltd.Börse TYO
-
Eisai Co., Ltd.Börse Freiverkehr OTC
-
Eisai Co., Ltd.Börse Freiverkehr OTC
-
ISIN JP3160400002
WKN 855526
Symbol EII
Währung
EUR
Börse
Börse Frankfurt Zeitzone: Europe/Berlin
Marktkapitalisierung
25.848.000.000
Mitarbeiter
11.322
Zahlte zuletzt am 30.03.2021 eine Dividende von 80 JPY . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht
Die Dividendenrendite
entsprach 100.475,79 % p. a.
beim aktuellen Kurs von 82,5 EUR -4,62%
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 82,5 EUR -4,62%
Portrait der Eisai Aktie
Das Unternehmen Eisai aus Japan beschäftigt 11.322 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Chemie, Biotechnologie, Pharma tätig.
Eisai ist in mehr als 52 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter UBS ETF (LU) MSCI Japan Socially Responsible UCITS ETF (hedged to EUR) A-acc gewichtet Eisai mit 2,51% im ETF.
Entdecke die 6 ETFs in denen Eisai am höchsten gewichtet ist Insgesamt in 52 ETFs enthalten
Dir gefallen die Informationen zu Eisai?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Eisai?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Eisai?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Eisai?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
35 News & Informationen zur Eisai Aktie
Global $5.42 Bn Anti-Obesity Drugs Markets to 2030: Focus on Prescription Drugs (Rx), OTC Drugs, Monotherapies, & Polytherapies
/PRNewswire/ — The
Global $5.42 Bn Anti-Obesity Drugs Markets To 2030: Focus On Prescription Drugs (Rx), OTC Drugs, Monotherapies, & Polytherapies
DUBLIN, Aug. 31, 2021 /PRNewswire/ — The “Antiobesity Global Market Report 2021: COVID-19 Impact and Recovery to 2030” report has been added to
Biogen provides free Aduhelm as U.S. clinics await Medicare payment
Biogen Inc is providing its controversial and expensive new Alzheimer’s drug free of charge for some patients amid slow claim reviews by Medicare, according to…
Global Anti-Obesity Drugs Markets, 2021-2026: Focus On Peripherally & Centrally Acting Drugs, Monotherapies, Polytherapies
DUBLIN, Aug. 23, 2021 /PRNewswire/ — The “Global Anti-Obesity Drugs Market (2021-2026) by Drug Type, Drug Class, Medication, Distribution Channel, Geography,
The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to domin…
Eisai Co., Ltd. (ESALF) Management on Q1 2022 Results – Earnings Call Transcript
Eisai Co., Ltd. (OTCPK:ESALF) Q1 2022 Earnings Conference Call August 04, 2021 03:00 AM ET Company Participants Ryohei Yanagi – Executive Vice President & Chief Financial Officer Ivan…
Global $191 Billion Orphan Drugs Markets To 2026: Therapeutic Applications In Rare And Orphan Diseases, Regulatory Framework, Patents, And Innovations
DUBLIN, Aug. 5, 2021 /PRNewswire/ — The
Global Osteoporosis Therapeutics Market to Reach $13.1 Billion by 2024
/PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…
Eisai Inc. Announces the Appointment of Dr. Janna Hutz as President of the Eisai Center for Genetics Guided Dementia Discovery
WOODCLIFF LAKE, N.J., Aug. 5, 2021 /PRNewswire/ — Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the appointm…
Biogen, Eisai report design of real-world study of Alzheimer's treatment
Biogen Inc and partner Eisai Co Ltd on Thursday revealed the design of an upcoming study of their controversial Alzheimer’s treatment, Aduhelm.
Biogen : Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)
TOKYO, July 29, 2021 /PRNewswire/ — Eisai Co., Ltd. and Biogen Inc. today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab — granted… | July 29, 2021
Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)
/PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,…
Global Anti-epileptic Drugs Market to surpass US$ 7,344.9 Million by 2028, Says Coherent Market Insights (CMI)
SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) — Global Anti-epileptic Drugs Market to surpass US$ 7,344.9 Million by 2028, Says Coherent Market Insights (CMI)…
Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021
CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its…
Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data
Item-level analysis from EMERGE trial shows consistency in slowing decline across cognitive, functional and behavioral measures in early Alzheimer’s…
Tempest Therapeutics : BUSINESS (Form 8-K)
TEMPEST'S BUSINESS
Overview
Tempest is a clinical-stage oncology company focused on leveraging its deep scientific understanding of cancer… | July 16, 2021
T. Rowe Price Japan Fund Buys Eisai, Trims Softbank
GuruFocus Article or News written by Margaret Moran and the topic is about: Japan-focused fund releases its 2nd-quarter 2021 portfolio updates
Japan stocks higher at close of trade; Nikkei 225 up 2.25% By Investing.com
Japan stocks higher at close of trade; Nikkei 225 up 2.25%
Biogen Says FDA Approves Updated Label For Alzheimer's Drug Aduhelm Injection – Quick Facts
(RTTNews) – Biotechnology company Biogen, Inc. (BIIB) and Japanese pharma firm Eisai Co. Ltd. (ESALY.PK, ESALF.PK) announced Thursday that the U.S…
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia…
Global Anesthetics Market Report 2020: Market is Expected to Grow from $5.7 Billion in 2029 to $6 Billion in 2023 – Forecast to 2025 & 2030
/PRNewswire/ — The
Global $79.2 Billion Kinase Inhibitors Markets to 2026: Antineoplastic Agents, Age-related Macular Degeneration (AMD), Immunosuppressant
/PRNewswire/ — The
Global $79.2 Billion Kinase Inhibitors Markets To 2026: Antineoplastic Agents, Age-related Macular Degeneration (AMD), Immunosuppressant
DUBLIN, July 2, 2021 /PRNewswire/ — The
Japan stocks lower at close of trade; Nikkei 225 down 0.07% By Investing.com
Japan stocks lower at close of trade; Nikkei 225 down 0.07%
Eisai : Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
FOR IMMEDIATE RELEASE
June 29, 2021
Listed Company Name:
… | June 29, 2021
Eisai Inc. Announces the Appointment of Dr. Andree Amelsberg as Vice President, U.S. Medical Affairs, Oncology Business Group
/PRNewswire/ — Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Andree Amelsberg, M.D., MBA, as…
Japan stocks higher at close of trade; Nikkei 225 up 0.66% By Investing.com
Japan stocks higher at close of trade; Nikkei 225 up 0.66%
Japanese shares track Wall St higher, cautious outlook caps gains
Japanese shares rose on Friday, led by cyclical and technology stocks, as markets tracked a strong finish on Wall Street, although the gains were capped by a cautious outlook of U.S. equities and…
Eli Lilly to Seek FDA Approval for Alzheimer’s Drug
The drugmaker said donanemab, which is similar in ways to a recently approved therapy from Biogen, has been designated for an expedited review.
Biogen : Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., June 23, 2021 /PRNewswire/ — Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy… | June 23, 2021
Biogen : and Eisai Update for the Alzheimer's Disease Community
CAMBRIDGE, Mass. and WOODCLIFF LAKE, N.J., June 23, 2021 – Biogen and Eisai Inc., U.S. subsidiary of Eisai Co., Ltd. today issued the following statement:
On… | June 23, 2021
Folliculotropic Mycosis Fungoides Treatment Market 2021–2031 Global Analysis, Size, Share, Incredible Growth, Detailed Industry Analysis and Business Prospects | FMI
Folliculotropic mycosis fungoides (FMF), one type of cutaneous T-cell lymphoma is a rare disease in which white blood cells, namely lymphocytes become harmful
Biogen : Evaluation of aducanumab efficacy in early Alzheimer's disease at AD/PD
Evaluation of aducanumab efficacy in early Alzheimer's disease
Samantha Budd Haeberlein,1 Stephen Salloway,2 Paul S. Aisen,3 Frederik Barkhof,4,5 Carmen… | March 13, 2021
Global Alzheimer's Disease Diagnostics and Therapeutics Market to 2025: Use of Biomarkers in Diagnosis and Drug Development & Large Number of Drugs in Pipeline
Dublin, Jan. 14, 2021 (GLOBE NEWSWIRE) — The
Eisai : Lilly Alzheimer's drug slows mental, functional decline in mid-stage trial, shares jump
Eli Lilly and Co said on Monday a
small trial of its experimental Alzheimer's drug found that it
slowed by about a third the rate of decline in a combined
measure of cognition and function in patients… | January 11, 2021